Parallax Volatility Advisers, L.P. Neurocrine Biosciences Inc Put Options Transaction History

Parallax Volatility Advisers, L.P.

11 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2023 Nov 14, 2023	BUY	$94.02 - $117.1 $2.83 Million - $3.52 Million	30,100 New	30,100 $3.39 Million
Q3 2021 Nov 15, 2021	SELL	$86.18 - $99.03 $396,428 - $455,538	-4,600 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$89.43 - $102.27 $411,378 - $470,442	4,600 New	4,600 $447,000
Q1 2021 May 14, 2021	SELL	$87.57 - $119.4 $4.18 Million - $5.7 Million	-47,700 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$87.57 - $119.4 $3.77 Million - $5.15 Million	43,100 Added 936.96%	47,700 $4.64 Million
Q4 2020 Feb 16, 2021	SELL	$86.91 - $108.33 $8,691 - $10,833	-100 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$86.91 - $108.33 $399,786 - $498,318	4,600 New	4,600 $441,000
Q3 2020 Nov 13, 2020	SELL	$96.16 - $135.15 $125,008 - $175,695	-1,300 Reduced 92.86%	100 $10,000
Q2 2020 Aug 14, 2020	BUY	$85.09 - $130.36 $110,617 - $169,468	1,300 Added 1300.0%	1,400 $170,000
Q4 2018 Feb 14, 2019	SELL	$68.32 - $124.36 $2.04 Million - $3.72 Million	-29,900 Reduced 99.67%	100 $7,000
Q4 2017 Feb 14, 2018	BUY	$58.53 - $77.59 $1.76 Million - $2.33 Million	30,000	30,000 $2.33 Million

638

93.8M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $14.5B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Parallax Volatility Advisers, L.P., based on Form 13F filings with the SEC.

Stay updated on Parallax Volatility Advisers, L.P. with notifications on news.